Predictors of cardiovascular response to methamphetamine administration in methamphetamine-dependent individuals

American Journal on Addictions

Volumn 17, Issue 2, 2008, Pages 103-110

  Fleury, Gilles ^a,b   De La Garza II, Richard ^a   Mahoney III, James J ^a   Evans, Sarah E ^a   Newton, Thomas F ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hopital Montfort Hospital   (Canada)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE; SODIUM CHLORIDE;

ADULT; ALCOHOLISM; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANNABIS ADDICTION; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DEPENDENCE; ETHNIC DIFFERENCE; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SUBSTANCE ABUSE; TOBACCO DEPENDENCE;

ADULT; ALCOHOLISM; AMPHETAMINE-RELATED DISORDERS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MARIJUANA ABUSE; METHAMPHETAMINE; RISK; SEX FACTORS; STREET DRUGS;

EID: 41949136540     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701861078     Document Type: Article

References (42)

1. French MT, Martin RF. The costs of drug abuse consequences: a summary of research findings. J Subst Abuse Treat. 1996;13:453-466.
2. DAWN. http://dawninfo.samhsa.gov/pubs/.2005.
3. SAMHSA. http://www.oas.samhsa.gov/.2002.
4. United Nations. http://www.unodc.org/pdf/trends2003_www_E.pdf. 2003.
5. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta. 1993;1144:249-263.
6. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406-433.
7. Schindler CW, Zheng JW, Tella SR, Goldberg SR. Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys. Pharmacol Biochem Behav. 1992;42:791-796.
8. Frances RJ, Miller SI, Mack AH, eds. Clinical Textbook of Addictive disorders. 3rd ed. New York: Guilford Press; 2005:684.
9. Newton TF, De La Garza R II, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav. 2005;82:90-97.
10. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med. 1999;170:214-219.
11. Varner KJ, Ogden BA, Delcarpio J, Meleg-Smith S. Cardiovascular responses elicited by the "binge" administration of methamphetamine. J Pharmacol Exp Ther. 2002;301:152-159.
12. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003;24:369-373.
13. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999;44:359-368.
14. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007;120:165-171.
15. Johnson BA, Wells LT, Roache JD, Wallace C, Ait-Daoud N, Wang Y. Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies. Am J Hypertens. 2005;18:813-822.
16. Wagner GC, Tekirian TL, Cheo CT. Sexual differences in sensitivity to methamphetamine toxicity. Journal of Neural Transmission. 1993;93:67-70.
17. Dluzen DE, McDermott JL. Estrogen, testosterone, and methamphetamine toxicity. Ann NY Acad Sci. 2006;1074:282-294.
18. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59:966-974.
19. Bae SC, Lyoo IK, Sung YH, et al. Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend. 2006;81:83-88.
20. Brecht ML, O'Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29:89-106.
21. Kosten TR, Kosten TA, McDougle CJ, et al. Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry. 1996;39:147-148.
22. Sofuoglu M, Nelson D, Dudish-Paulsen S, Lexau B, Pentel PR, Hatsukami DK. Predictors of cardiovascular response to smoked cocaine in humans. Drug Alcohol Depend. 2000;57:239-245.
23. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA. 1991;265:1152-1154.
24. Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine- associated cardiomyopathy: tip of the iceberg? Journal of Toxicology. Clinical Toxicolgy. 2003;41:981-986.
25. Yu Q, Montes S, Larson DF, Watson RR. Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci. 2002;71:953-965.
26. Mendelson J, Jones RT, Upton R, Jacob P III. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther. 1995;57:559-568.
27. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627-633.
28. Matsumoto T, Kamijo A, Miyakawa T, et al. Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction. 2002;97:809-817.
29. Newton TF, Roache JD, De La Garza R II, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31:1537-1544.
30. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49:81-96.
31. Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36:1182-1190.
32. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
33. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346.
34. Souza Neto EP, Neidecker J, Lehot JJ. [To understand blood pressure and heart rate variability]. Ann Fr Anesth Reanim. 2003;22:425-452.
35. Tuncel M, Wang Z, Arbique D, Fadel PJ, Victor RG, Vongpatanasin W. Mechanism of the blood pressure-raising effect of cocaine in humans. Circulation. 2002;105:1054-1059.
36. Perez-Reyes M, White WR, McDonald SA, et al. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol. 1991;14:352-358.
37. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 1975;18:287-297.
38. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42(11 Suppl):64S-70S.
39. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42(11 Suppl):58S-63S.
40. Newlin DB, Wong CJ, Stapleton JM, London ED. Intravenous cocaine decreases cardiac vagal tone, vagal index (derived in lorenz space), and heart period complexity (approximate entropy) in cocaine abusers. Neuropsychopharmacology. 2000;23:560-568.
41. Vongpatanasin W, Taylor JA, Victor RG. Effects of cocaine on heart rate variability in healthy subjects. Am J Cardiol. 2004;93:385-388.
42. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74:224-242.